Effects of a ketamine metabolite on synaptic NMDAR function

Nature

Volumn 546, Issue 7659, 2017, Pages E1-E3

  Suzuki, Kanzo ^a   Nosyreva, Elena ^a   Hunt, Kevin W ^b   Kavalali, Ege T ^a   Monteggia, Lisa M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; ELONGATION FACTOR 2 KINASE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ACTIVATION ENERGY; AMINO ACID; BRAIN; CELLS AND CELL COMPONENTS; CHEMICAL BINDING; DRUG; GENE EXPRESSION; GENETIC ANALYSIS; INHIBITION; METABOLITE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNAPSE;

EID: 85021156187     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22084     Document Type: Article

References (13)

1. Berman, R. M. et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351-354 (2000).
2. Zanos, P. et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533, 481-486 (2016).
3. Autry, A. E. et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91-95 (2011).
4. Nosyreva, E. et al. Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J. Neurosci. 33, 6990-7002 (2013).
5. Nosyreva, E., Autry, A. E., Kavalali, E. T. & Monteggia, L. M. Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade. Front. Mol. Neurosci. 7, 94 (2014).
6. Atasoy, D. et al. Spontaneous and evoked glutamate release activates two populations of NMDA receptors with limited overlap. J. Neurosci. 28, 10151-10166 (2008).
7. Gideons, E. S., Kavalali, E. T. & Monteggia, L. M. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc. Natl Acad. Sci. USA 111, 8649-8654 (2014).
8. Lukas, G., Brindle, S. D. & Greengard, P. The route of absorption of intraperitoneally administered compounds. J. Pharmacol. Exp. Ther. 178, 562-564 (1971).
9. Collingridge, G.L. et al. Antidepressant actions of ketamine versus hydroxynorketamine. Biol. Psychiatry 81, e65-e67 (2016).
10. Zanos, P. et al. Reply to: antidepressant actions of ketamine versus hydroxynorketamine. Biol. Psychiatry 81, e69-e71 (2016).
11. Singh, J. B. et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol. Psychiatry 80, 424-431 (2016).
12. Moaddel, R. et al. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in a 7 nicotinic acetylcholine receptors. Eur. J. Pharmacol. 698, 228-234 (2013).
13. Kotermanski, S. E., Wood, J. T. & Johnson, J. W. Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J. Physiol. (Lond.) 587, 4589-4604 (2009).